Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
MedImmune, LLC
Scientific Title
A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination With Durvalumab in Selected Advanced Solid Tumors